Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-321 + Depatuxizumab mafodotin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-321 | ABBV321|ABBV 321|Serclutamab talirine | EGFR Antibody 60 | ABBV-321 (serclutamab talirine) is an antibody-drug conjugate (ADC) consisting of a monoclonal EGFR antibody and the cytotoxic agent, pyrrolobenzodiazepine, which may lead to inhibition of tumor growth (PMID: 32847977). | |
Depatuxizumab mafodotin | ABT-414|depatux-m | EGFR Antibody 60 | Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to an anti-microtubule drug, which delivers the cytotoxic agent to EGFR-expressing cells, potentially resulting in increased tumor cell death and decreased growth of EGFR-overexpressing tumors (PMID: 26846818, PMID: 29075855, PMID: 31747009, PMID: 32371586). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|